Description: Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Home Page: eledon.com
ELDN Technical Analysis
19900 MacArthur Boulevard
Irvine,
CA
92612
United States
Phone:
949 238 8090
Officers
| Name | Title |
|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | CEO & Non Independent Director |
| Dr. Steven N. Perrin Ph.D. | Pres, Chief Scientific Officer & Non Independent Director |
| Mr. Paul Sean Little | CFO & Principal Accounting Officer |
| Mr. Bryan E. Smith J.D. | Gen. Counsel, Corp. Sec. & Chief Compliance Officer |
| Mr. John Herberger | VP of Technical Operations |
| Mr. Gregory J. Flesher | Consultant |
| Dr. Jeffrey D. Bornstein | Chief Medical Officer |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 2.1896 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2477 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-09-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |